DRIO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
DarioHealth Corp (DRIO) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 to invest. The company is currently facing significant financial challenges, including declining revenue, increased net losses, and negative earnings per share. Additionally, technical indicators suggest a bearish trend, and there are no strong trading signals or positive catalysts to support a buy decision at this time.
The technical indicators for DRIO are bearish. The MACD histogram is negative and expanding downward, indicating a weakening trend. The RSI is at 28.361, which is neutral but close to being oversold. Moving averages are bearish, with SMA_200 > SMA_20 > SMA_5. The stock is trading below key support levels, with the next support at 7.436. Overall, the technical outlook suggests a downward trend.
The company has signed 85 new agreements in 2025, expecting $12.9 million in annual recurring revenue. Q4 2025 revenue showed a slight sequential improvement compared to Q3 2025, and gross margins have improved to 65.09%, up 17.79% YoY.
Net income and EPS have also dropped significantly, raising concerns about profitability and investor confidence. Technical indicators are bearish, and there are no recent trading signals or significant insider activity to suggest positive sentiment.
In Q4 2025, revenue dropped by 31.21% YoY to $5.23 million. Net income fell by 26.34% YoY to -$9.03 million, and EPS decreased by 63.34% YoY to -1.14. However, gross margins improved to 65.09%, up 17.79% YoY, and operating expenses decreased by 28% YoY.
No recent analyst rating or price target changes are available for DRIO. However, the overall sentiment appears to be negative due to declining financial performance and bearish technical indicators.
